Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY: NVO )

61.30 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Apr 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 178,790
Open 61.30
Bid (Size) 62.31 (4)
Ask (Size) 62.35 (8)
Prev. Close 61.30
Today's Range 61.30 - 61.30
52wk Range 57.00 - 148.15
Shares Outstanding N/A
Dividend Yield 3.59%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Trump Administration Considers Lowering US Drug Prices To International Levels: Report
The Trump Administration is reportedly mulling over a policy to match U.S. drug prices with those in other developed nations. 
Via Benzinga
Topics Government
Exposures Political
Eli Lilly Nails Oral GLP-1 Trial—Here’s What It Means for LLY
Take a deep dive into Eli Lilly's latest clinical GLP-1 results that sent shares soaring. The company has a big opportunity to serve needle-phobic patients. 
Via MarketBeat

Performance

YTD
-29.96%
-29.96%
1 Month
-18.62%
-18.62%
3 Month
-23.92%
-23.92%
6 Month
-47.04%
-47.04%
1 Year
-52.35%
-52.35%

More News

Read More
Novo Nordisk Investors Just Got Terrible News. Should You Sell the Stock?
Via The Motley Fool
Is Eli Lilly Stock a Buy?
Via The Motley Fool
Eli Lilly Positioned To Dominate Obesity Market With Oral Option, Analyst Initiates With Confidence
Via Benzinga
Why Novo Nordisk Stock Popped Today
Via The Motley Fool
Exposures Product Safety
Novo Nordisk Just Leapfrogged Eli Lilly With A Weight-Loss Pill; Shares Pop
Via Investor's Business Daily
Exposures Product Safety
Think It's Too Late to Buy Novo Nordisk? Here's the Biggest Reason Why There's Still Time.
Via The Motley Fool
Down 60%, Is This Growth Stock Too Cheap to Ignore?
Via The Motley Fool
Novo Nordisk's FDA Submission For Obesity Pill Gets Retail Traders Buzzing Amid Fierce Eli Lilly Rivalry
Via Stocktwits
Exposures Product Safety
Down 61%, Is Novo Nordisk Stock Worth Buying on the Dip?
Via The Motley Fool
Did Eli Lilly Just Say Checkmate to Novo Nordisk?
Via The Motley Fool
Eli Lilly's Experimental Weight Loss Pill Succeeded in Its First Pivotal Trial. Is It Time to Buy?
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
ETF Shake-Up: UNH's Meltdown Meets LLY's Moonshot
Via Benzinga
Topics ETFs
Where Will Eli Lilly Be in 5 Years?
Via The Motley Fool
Netflix, UnitedHealth, Novo Nordisk, Tesla And Trump Media: Why These 5 Stocks Are On Investors' Radars Today
Via Benzinga
Topics Government
Exposures Political
Eli Lilly Rallies Over 14%, Notches Best Day Since June 2000 On Oral Weight-Loss Drug Results: Analysts React
Via Benzinga
Novo Nordisk May Lag Behind Eli Lilly In Cardiometabolic Race, Analyst Downgrades Stock
Via Benzinga
Lilly's Diabetes Pill Clears Major Trial, Analyst Points To Global Potential
Via Benzinga
Why Eli Lilly Stock Is Soaring Today, While Novo Nordisk and Viking Therapeutics Slide
Via The Motley Fool
Mark Cuban Says This Trump Healthcare Order 'Could Save Hundreds Of Billions'
Via Benzinga
Topics Government
Exposures Political
This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
Intuit To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Eli Lilly’s Weight Loss Pill Succeeds In Phase 3 Trials On Type-2 Diabetes Patients
Via Stocktwits
Topics Economy Government Stocks
Exposures Interest Rates Political US Equities
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.